Abstract
Background
Depression has been shown to be a common co-morbidity in diabetes. From a public health point of view, there is a lack of population-based studies regarding the use of antidepressant medication in non-clinical samples of people with diabetes. The objective of the present study was to provide demographic and clinical information about the use of antidepressant medication in a representative community sample of people with diabetes.
Method
The Canadian Community Health Survey 1.2 (CCHS 1.2) is a cross-sectional survey that collects information related to health status, health-care utilization and health determinants of the Canadian general population. Diabetes presence was ascertained by self-report of physician diagnosis. Depression and anxiety were assessed using a modified version of the World Mental Health Composite International Diagnostic Interview. Antidepressant use was determined through self-report.
Results
The population prevalence of self-reported antidepressant use in the past 12 months was 8.4% (SE = 0.95) among people with diabetes (n = 1,662). People who took antidepressants had higher average body mass index (M = 32.6, SD = 6.5) than those not taking antidepressants (M = 29.2, SD = 5.7). The use of antidepressants was associated with poorer health status and higher number of co-morbid chronic conditions. Half of diabetes subjects who used antidepressant medication in the last year did not have a lifetime history of major depression.
Conclusions
In a community sample of people with diabetes, the prevalence of antidepressant use exceeded the prevalence of major depression. Anxiety disorders and other somatic chronic conditions were associated with the prescription of antidepressant medication in people with diabetes, but without a history of major depression.
Similar content being viewed by others
References
Andrews G, Slade T (2001) Interpreting scores on the Kessler Psychological Distress Scale (K10). Aust N Z J Public Health 25:494
Beck CA, Patten SB, Williams JVA, Jian Li W, Currie SR, Maxwell CJ, El-Guebaly N (2005) Antidepressant utilization in Canada. Soc Psychiatry Psychiatr Epidemiol 40:799–807
Cairney J, Veldhuizen S, Wade TJ, Kurdyak P, Streiner DL (2007) Evaluation of 2 measures of psychological distress as screeners for depression in the general population. Can J Psychiatry 52:111–120
Demyttenaere K, Jaspers L (2008) Bupropion and SSRI-induced side effects. J Psychopharmacol 22:792–804
Deshmukh R, Franco K (2003) Managing weight gain as a side effect of antidepressant therapy. Cleve Clin J Med 70:614–623
Furukawa TA, Kessler RC, Slade T, Andrews G (2003) The performance of the K6 and K10 screening scales for psychological distress in the Australian National Survey of Mental Health and Well-Being. Psychol Med 33:357–362
Ghaemi SN, Lenox MS, Baldessarini RJ (2001) Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 62:565–569
Gonzalez JS, Peyrot M, McCarl LA et al (2008) Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 31:2398–2403
Gonzalez JS, Safren SA, Cagliero E, Wexler DJ, Delahanty L, Wittenberg E et al (2007) Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 30:2222–2227
Goodnick PJ (2001) Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry 13:31–41
Hirschfeld R, Keller M, Panico S, Arons B, Barlow D, Davidoff F, Endicott J, Froom J, Goldstein M, Gorman J, Marek R, Maurer T, Meyer R, Phillips K, Ross J, Schwenk T, Sharfstein S, Thase M, Wyatt R (1997) The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277:333–340
Idler EL, Benyamini Y (1997) Self-rated health and mortality: a review of twenty-seven community studies. J Health Soc Behav 38:21–37
Katon W, Lin EHB, Kroenke K (2007) The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 29:147–155
Katon WJ, Von Korff M, Lin EHB, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T (2004) The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 61:1042–1049
Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P et al (2005) The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 28:2668–2672
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J (2000) A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462–1470
Kennedy SH (2006) A review of antidepressant treatments today. Eur Neuropsychopharmacol 16:S619–S623
Kessler RC, Ustün TB (2004) The World Mental Health (WMH) survey initiative version of the World Health Organization (WHO) composite. International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 13:93–121
Kessler R, Andrews G, Colpe L, Hiripi E, Mroczek D, Normand S, Walters E, Zaslavsky A (2002) Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 32:959–976
Lin EHB, Von Korff M (2008) Mental disorders among persons with diabetes-Results from the World Mental Health Surveys. J Pyschosom Res 65:571–580
Lustman PJ, Freedland KE, Griffith LS, Clouse RE (2000) Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23:618–623
Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, McGill JB (1997) Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 59:241–250
Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE (1998) Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 129:613–621
McCollum M, Ellis SL, Regensteiner JG, Zhang W, Sullivan PW (2007) Minor depression and health status among US adults with diabetes mellitus. Am J Manag Care 13:65–72
McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH (2006) The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 5:157–168
McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH (2006) The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 5:523–537
Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors. JAMA 289:76–79
National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6:51–209
Ohayon MM, Caulet M, Priest RG, Guilleminault C (1998) Psychotropic medication consumption patterns in the UK general population. J Clin Epidemiol 51:273–283
Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ (2004) Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 57:1096–1103
Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401
Rubin RR, Ma Y, Marrero DG, Peyrot M, Barrett-Connor EL, Kahn SE et al (2008) Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 31:420–426
Statistics Canada (2002) A profile of disability in Canada. Canadian Research Index 2002, Ottawa
The Diabetes Prevention Program Research Group (2005) Depression symptoms and antidepressant medicine use in diabetes prevention program participants. Diabetes Care 28:830–837
Tunks ER, Weir R, Crook J (2008) Epidemiologic perspective on chronic pain treatment. Can J Psychiatry 53:235–242
Williams JW Jr, Katon W, Lin EHB, Noel PH, Worchel J, Cornell J, Harpole L, Fultz BA, Hunkeler E, Mika VS, Unutzer J (2004) The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann Intern Med 140:1015–1024
Wittchen HU (1994) Reliability and validity studies of the WHO-Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 28:57–84
Acknowledgments
This analysis is based on Statistics Canada’s Canadian Community Health Survey, Cycle 1.2 (2005), public use microdata file which contains anonymized collected data. All computations on these microdata were prepared by Anna Ivanova, Danit Nitka, and Norbert Schmitz, and the responsibility for the use and interpretation of these data is entirely that of the authors. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. This research was funded by the Canadian Institutes for Health Research (CIHR Grant MOP-79464) and a FRSQ Chercheur-Boursier fellowship to Dr Schmitz.
Conflict of interest statement
Nothing to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ivanova, A., Nitka, D. & Schmitz, N. Epidemiology of antidepressant medication use in the Canadian diabetes population. Soc Psychiat Epidemiol 45, 911–919 (2010). https://doi.org/10.1007/s00127-009-0129-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00127-009-0129-y